L
Luqa Pharmaceuticals
Luqa Pharmaceuticals is a China-focused company
About Luqa Pharmaceuticals
Luqa Pharmaceuticals operates as a specialty healthcare company with a strategic focus on the Chinese market. Founded in 2010 by Robert Braithwaite, the firm was established to bridge the gap between Western pharmaceutical and dermo-cosmetic companies and the rapidly expanding Chinese healthcare sector. Braithwaite, with his prior experience as the founder and CEO of a leading specialty pharmaceutical company in China, possesses deep-seated knowledge of the local market dynamics, which has been instrumental in shaping Luqa's trajectory.
The company's business model centers on acquiring, developing, and commercializing differentiated healthcare products. Luqa actively seeks out promising assets from international partners to bring into China, managing the entire lifecycle from in-licensing and regulatory approval to marketing and sales. Its revenue is generated through the direct sale of these products within the country. The firm has established a robust commercial infrastructure, including a dedicated sales and marketing team, which allows it to effectively reach its target clients, primarily physicians and hospitals within the aesthetic and dermatology fields.
Luqa's product portfolio is a curated selection of dermo-cosmetic and medical aesthetic solutions. One of its key products is Verrutop, a topical solution for treating difficult-to-treat warts. Another significant offering is Pluryal, a line of hyaluronic acid dermal fillers and skin boosters used for aesthetic procedures. The company also markets the Biretix and Endocare brands, which are dermo-cosmetic lines aimed at addressing acne and skin photoaging, respectively. This portfolio demonstrates a clear focus on the specialty care segment, particularly in medical aesthetics and dermatology, which are high-growth areas within China. Through its targeted in-licensing strategy and strong commercial execution, Luqa has positioned itself as a key partner for international firms looking to access the lucrative Chinese healthcare market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Huangpu, China
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 55.3/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | May 2018 | $15M | $60M | Cenova Capital | — |
| SERIES A✓Equity / VC | Jun 2015 | $15M | $60M | Morningside | — |
Growth signals
Latest recorded traffic for Luqa Pharmaceuticals is 310 monthly website visits. Luqa Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Morningside
Cenova Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Luqa Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Luqa Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.